“The Promise of Interleukin-2 Therapy” 2024: A Landmark Event in Immunotherapy Research

The 2024 edition of "The Promise of Interleukin-2 Therapy" chaired by David Klatzmann (TiilT project coordinator), concluded successfully in Paris after four days of engaging scientific exchange, held from September 4 to 7. With over 300 participants from around the globe, the event reaffirmed its status as a landmark event in the field of IL-2 research and immunotherapy.

This year’s program offered a comprehensive exploration of IL-2, covering topics that ranged from fundamental immunology to the latest clinical trial results. Discussions spanned across key areas including autoimmune and inflammatory diseases, allergy, transplantation, and cancer.

This high-profile meeting brought together leading scientists, pharmaceutical companies, consultants, and venture capitalists, underscoring its importance within the field of interleukin-2 research.

Consortium partners were prominently featured in the program: Christoph Binder (MUW) and Ziad Mallat (INSERM) were invited to deliver presentations, highlighting the consortium’s scientific progress and contributions to the field, while J. Lyons (ILTOO) chaired a round-table discussion.